BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33371010)

  • 1. LDCT lung cancer screening in populations at different risk for lung cancer.
    Teles GBDS; Macedo ACS; Chate RC; Valente VAT; Funari MBG; Szarf G
    BMJ Open Respir Res; 2020 Feb; 7(1):. PubMed ID: 33371010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of lung cancer risk model (PLCO
    Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
    Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.
    Pinsky PF; Gierada DS; Black W; Munden R; Nath H; Aberle D; Kazerooni E
    Ann Intern Med; 2015 Apr; 162(7):485-91. PubMed ID: 25664444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
    Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
    EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
    Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval.
    Silva M; Milanese G; Sestini S; Sabia F; Jacobs C; van Ginneken B; Prokop M; Schaefer-Prokop CM; Marchianò A; Sverzellati N; Pastorino U
    Eur Radiol; 2021 Apr; 31(4):1956-1968. PubMed ID: 32997182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of Risk Factor-Based Guidelines and Model-Based Chest CT Lung Cancer Screening in World Trade Center-Exposed Fire Department Rescue/Recovery Workers.
    Cleven KL; Vaeth B; Zeig-Owens R; Colbeth HL; Jaber N; Schwartz T; Weiden MD; Markowitz SB; Silvestri GA; Prezant DJ
    Chest; 2021 May; 159(5):2060-2071. PubMed ID: 33279511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Jonas DE; Reuland DS; Reddy SM; Nagle M; Clark SD; Weber RP; Enyioha C; Malo TL; Brenner AT; Armstrong C; Coker-Schwimmer M; Middleton JC; Voisin C; Harris RP
    JAMA; 2021 Mar; 325(10):971-987. PubMed ID: 33687468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor.
    Wilson DO; Weissfeld J
    Lung Cancer; 2015 Jul; 89(1):31-7. PubMed ID: 25863905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol and Rationale for the International Lung Screening Trial.
    Lim KP; Marshall H; Tammemägi M; Brims F; McWilliams A; Stone E; Manser R; Canfell K; Weber M; Connelly L; Bowman RV; Yang IA; Fogarty P; Mayo J; Yee J; Myers R; Atkar-Khattra S; Lam DCL; Rosell A; Berg CD; Fong KM; Lam S;
    Ann Am Thorac Soc; 2020 Apr; 17(4):503-512. PubMed ID: 32011914
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the accuracy of the PLCO
    Jantzen R; Ezer N; Camilleri-Broët S; Tammemägi MC; Broët P
    CMAJ Open; 2023; 11(2):E314-E322. PubMed ID: 37041013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Tammemägi MC; Darling GE; Schmidt H; Llovet D; Buchanan DN; Leung Y; Miller B; Rabeneck L
    Lung Cancer; 2021 Jun; 156():31-40. PubMed ID: 33887677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography.
    Vogel-Claussen J; Lasch F; Bollmann BA; May K; Kuhlmann A; Schmid-Bindert G; Kaaks R; Barkhausen J; Bohnet S; Reck M
    Rofo; 2022 Dec; 194(12):1333-1345. PubMed ID: 35917826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Clinical Implementation of Lung Cancer Screening-Evaluating Processes to Improve Screening Guidelines-Concordance.
    Carroll NM; Burnett-Hartman AN; Joyce CA; Kinnard W; Harker EJ; Hall V; Steiner JS; Blum-Barnett E; Ritzwoller DP
    J Gen Intern Med; 2020 Apr; 35(4):1143-1152. PubMed ID: 31974902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Different Approaches to Leveraging Historical Smoking Exposure Data to Better Select Lung Cancer Screening Candidates: A Retrospective Validation Study.
    Kats DJ; Adie Y; Tlimat A; Greco PJ; Kaelber DC; Tarabichi Y
    Nicotine Tob Res; 2021 Aug; 23(8):1334-1340. PubMed ID: 32974635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
    Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
    J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.